Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia

Journal of Clinical Investigation

Volumn 104, Issue 4, 1999, Pages 459-467

  Hill, Geoffrey R ^a   Teshima, Takanori ^a,b   Gerbitz, Armin ^a   Pan, Luying ^a   Cooke, Kenneth R ^a,b   Brinson, Yani S ^a   Crawford, James M ^c   Ferrara, James L M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CYTOTOXIC LYMPHOCYTE; DIGESTIVE SYSTEM INJURY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0032717103     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6896     Document Type: Article

References (53)

1. Truitt, R., Johnson, B., and McCabe, C. 1997. Graft versus leukemia. Marcel Dekker Inc.. New York, NY. 385-424.
2. Krenger, W., Hill, G., and Ferrara, J. 1997. Cytokine cascades in acute graft-versus-host disease. Transplantation. 64:553-558.
3. Kichian, K., Nestel, P.P., Kim, D., Ponka, P., and Lapp, W.S. 1996. IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. J. Immunol. 157:2851-2856.
4. Nestel, P.P., Price, K.S., Seemayer, T.A., and Lapp, W.S. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175:405-413.
5. Hill, G.R., Krenger, W., and Ferrara, J.L.M. 1997. The role of cytokines in acute graft-versus-host disease. Cytokines Cell. Mol. Ther. 3:257-265.
6. Ferrara, J.L.M., and Deeg, H.J. 1991. Graft versus host disease. N. Engl. J. Med. 324:667-674.
7. Nash, A., et al. 1992. Acute graft-versus-host disease analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 80:1838-1845.
8. Clift, R.A., et al. 1990. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 76:1867-1871.
9. Clift, R.A., et al. 1994. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 84:2036-2043.
10. Deeg, H.J., Spitzer, T.R., Cottler-Fox, M., Cahill, R., and Pickle, L.W. 1991. Conditioning-telated toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 7:193-198.
11. Hill, G.R., et al. 1997. Total body irradiation effects on acute graft versus host disease. The tole of gastrointestinal damage and inflammatory cytokines. Blood. 90:3204-3213.
12. Morse, H.C., Shen, F.W., and Hammerling, U. 1987. Genetic nomenclature for loci controlling mouse lymphocyte antigens, Immunogenetics. 25:71-78.
13. Page, D.M., Roberts, E.M., Peschon, J.J., and Hedrick, S.M. 1998. TNF receptor-deficient mice reveal striking differences between several models of thymocyte negative selection. J. Immunol. 160:120-133.
14. Pfeffer, K., et al. 1993. Mice deficient for the 55kD tumor necrosis factor receptor are resistant to endotoxin shock, yet succumb to L. monocytogenes infection. Cell. 73:457-467.
15. Erickson, S., et al. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 372:560-563.
16. Peschon J.J., et al. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160:943-952.
17. Hill, G.R., et al. 1998. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:115-123.
18. Cooke, K.R., et al. 1996. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood. 8:3230-3239.
19. Su, H., Leite-Morris, K., Braun, L., and Biron, C. 1991. A role for transforming growth factor-beta 1 in regulating natural killer and T lymphocyte proliferative responses during acute infection with lymphocytic choriomeningitis virus. J. Immunol. 147:2717-2727.
20. Blatter, D.D., Crawford, J.M., and Ferrara, J.L.M. 1990. Nuclear magnetic resonance of hepatic graft-versus-host disease in mice. Transplantation. 50:1011-1018.
21. Snover, D.C, et al. 1985. A histopathological study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum. Pathol. 16:387-392.
22. Snover, D.C., Weisdorf, S.A., Ramsay, N.K., McGlave, P., and Kersey, J.H. 1984. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology. 4:123-130.
23. Panoskaltsis-Mortari, A., et al. 1997. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogenic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J. Clin. Infest. 100:1015-1027.
24. Sykes, M. 1996. Chimerism and central tolerance. Curr. Opin. Immunol. 8:694-703.
25. Cooke, K., et al. 1998. Tumor necrosis factot-α production to lipopolysaccaride stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J. Clin. Invest. 102:1882-1891
26. Shresta, S., Pham. C., Thomas, D., Braubert, T., and Ley, T. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10:581-587.
27. Teshima, T., et al. 1999. IL-11 sepatates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104:317-325.
28. Ballas, Z. 1986. Lymphokine-activated filler (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J. Immunol. 137:2380-2384.
29. Lehnert, S., and Rybka, W.B. 1994. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transplant. 13:473-477.
30. Merluzzi, V. 1985. Comparison of murine lymphokine-activated killer cells, natural killer cells, and cytotoxic T lymphocytes. Cell Immunol. 95:95-104.
31. Papadakis, V., Mackinnon, V., and Kernen, N. 1994. Differential effect of pre-transplant cytoreduction on recovery of day zero host circulating cells. Bone Marrow Transplant. 14:623-630.
32. Cailleau, C., Diu-Hercend, A., Ruuth, E., Westwood, R., and Carnaud, C. 1997. Treatment with neutralizing antibodies specific for IL-1 beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes. 46:937-940.
33. Kachel, D., and Martin, W. 1994. Cyclophosphamide-induced lung toxicity: mechanism of endothelial injury. J. Pharmacol. Exp. Ther. 268:42-46.
34. Exon, J., Henningsen, G., Koller, L., and Talcott, P. 1986. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats. Int. J. Immunopharmacol. 8:53-62.
35. Schwaighofer, H., et al. 1996. Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted BMT: influence of conditioning and hematopoietic reconstitution. Transplantation. 62:947-953.
36. Bertomeu, M., et al. 1990. Chemotherapy enhances endothelial cell reactivity to platelets. Clin. Exp. Metastasis. 8:511-518.
37. Piguet, P.F., Grau, G.E., Allet, B., and Vassalli, P.J. 1987. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J. Exp. Med. 166:1280-1289,
38. Wall, D.A., and Sheehan, K.C. 1994. The role of tumor necrosis factor-alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation. 57:273-279.
39. Shalaby, M.R., Fendly, B., Sheehan, K.C., Schreiber, R.D., and Ammann, A.J. 1989. Prevention of the graft-vs-host reaction in new-born mice by antibodies to tumor necrosis factor-alpha. Transplantation. 47:1057-1061.
40. Abhyankar, S., Gilliland, D.G., and Ferrara, J.L.M. 1993. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplant. 56:1518-1523.
41. Holler, E., et al. 1995. Modulation of acute graft-verses-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF-alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF-alpha (MAK 195F). Blood. 86:890-899.
42. Antin, J.H., et al. 1994. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 84:1342-1348.
43. Hattori, K., et al. 1998. Differential effects of anti-fas ligand and anti-tumor necrosis factor a antibodies on acute graft-versus-host disease pathologies, Blood. 91:4051-4055.
44. Antin, J.H., and Ferrara, J.L.M. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood. 80:2964-2968.
45. Braun, Y.M., et al. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657-661.
46. Baker, M.B., Altman, N.H., Podack, E.R., and Levy, RB. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183:2645-2656.
47. Tsukada, N., Kobata, T., Aizawa, Y., Yagita, H., and Okumura, K. 1999. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 93:2738-2747.
48. Robinet, E., et al. 1990. Evidence for tumor necrosis factor-α involvement in the optimal induction of class I allospecific cytoroxic T cells. J. Immunol. 144:4555-4561.
49. Koide, S., Inaba, K., and Steinman, R. 1987. Interleukin 1 enhances T-dependent immune responses by amplifying the function of dendritic cells. J. Exp. Med. 165:515-530.
50. Faherty, D.A., et al. 1992. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J. Immunol. 148:766-771.
51. I. Ranges, G., Figari, I., Espevik, T., and Palladino, M. 1987. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor. J. Exp. Med. 166:991-998.
52. Nash, R.A., and Storb, R. 1996. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr, Opin. Immunol. 8:674-680.
53. Panoskaltsis-Mortari, A., Lacey, D. Vallera, D., and Blazer, B. 1998. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 92:3960-3967.